- Founded in 2019, Cureleads works to transform patient lives across the MENA region by leading the path to cure specialty and rare diseases, led by its highly profiled industry leader founders.
Dubai UAE: Abdul Latif Jameel Health, part of international diversified family business Abdul Latif Jameel, and Cureleads, a Dubai, UAE and Beirut, Lebanon based pharmaceutical and medicinal distribution and marketing business working throughout the Middle East and North Africa, have announced a new agreement for the distribution of Butterfly Network, Inc.’s Butterfly iQ+ ultrasound solution in the UAE.
The innovative Butterfly iQ+ is the world's first single probe, whole-body handheld ultrasound solution that brings the power of ultrasound into assessment, diagnosis and treatment processes.
As part of its new agreement with Abdul Latif Jameel Health, Cureleads will register Butterfly iQ+ in the United Arab Emirates – already widely considered the healthcare hub for the Middle East – and start commercial sales in December 2022, bringing the technology to potentially more than 26,000 medical doctors practicing in public and private hospitals and facilities across the Emirates.
World Health Organization data suggests that over 4.7 billion people around the world lack access to medical imaging, from underserved communities in the United States to remote areas of Africa. The Butterfly iQ+ aims to remedy this situation. Fusing semiconductors and artificial intelligence, Butterfly has made it possible to usher in a new era of medical imaging and with it, transform healthcare.
With a very diverse populace, research estimates the UAE 2022 population at 10.08 million, more than double that in 2005 (4.58 million). Government data reports that there are more than 200 nationalities living and working in the UAE. Indians form the largest foreign community in the country, followed by Pakistanis, Bangladeshi, other Asians, Europeans and Africans.
This new collaboration will offer greater distribution of Butterfly iQ+ to physicians in the UAE thereby expanding the capabilities of practitioners working both within, and outside, primary care units such as hospitals and clinics, accelerating access to modern medical care for those who need it most.
Butterfly iQ+, is revolutionizing medical imaging. It is an innovative 3 in 1, single-probe, whole-body hand-held ultrasound solution, powered by the world’s only Ultrasound–on-Chip™ technology.
This point of care device with over 20 default presets is compatible with both iOS and Android smart devices and comes complete with battery back, wireless charging, customized app software and AI support.
Hailed as potentially the ‘stethoscope of the future’, the Butterfly iQ+ transforms what can sometimes be complex processes, into one connected and integrated bedside imaging system. Butterfly iQ+ uniquely unlocks access to ultrasound information at every point-of-care setting, no matter where that setting is.
Through this distribution, clinicians across the UAE will gain information they’ve never before had, empowering them to perform rapid assessments and to guide more informed clinical decision-making, diagnosis, and treatment.
Speaking about this new collaboration, Mohamad Rammal, Chief Executive Officer and Co-Founder, Cureleads, said: “My life’s purpose, and the purpose of Cureleads, is to create happy, healthy and meaningful lives. Our aim is to transform patient lives by leading the path to medical cures. When medical practitioners use the very latest technology of Butterfly IQ+, they will be guided by real time patient assessment.
“The Butterfly iQ+ is an innovative ultrasound solution which fits in the palm of a hand. We’re very much looking forward to introducing the market to this technology and seeing how it can help every patient across the UAE, the hub for medical innovation in Middle East.”
Akram Bouchenaki, Chief Executive Officer, Abdul Latif Jameel Health added: “Abdul Latif Jameel is addressing tangible real-world needs today, for a better tomorrow. We are focused on health care inclusion, accelerating access to modern medical care for those who need it most.
“We believe in realizing the true power of deep local knowledge, relationships, and partnerships to get the very best results for the communities we serve. I am proud to collaborate with Cureleads who share our vision of improving live and lives across the Global South.”
About Abdul Latif Jameel Health
Backed by Abdul Latif Jameel, one of the most respected diversified family businesses and investors with a 75-year heritage, deep roots, and established networks alongside a multi-sector presence in 30 countries across six continents, Abdul Latif Jameel Health is uniquely positioned as a trusted partner in realizing major innovations and opportunities in the healthcare world.
Abdul Latif Jameel Health reflects the Jameel family’s long-established commitment to innovating for a better future through Community Jameel, an international organization supporting science and technology-led solutions to global challenges. Community Jameel and MIT co-founded the Abdul Latif Jameel Clinic for Machine Learning in Health (Jameel Clinic) in September 2018– which has rapidly become the very epicenter of AI and healthcare at MIT – and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (Jameel Institute) co-founded with Imperial College London, in October 2019, using novel data analytics to reduce global risk of preventable disease most recently including the 2020 COVID-19 pandemic, and strengthening health systems in the most fragile settings.
Abdul Latif Jameel Health takes this commitment into the commercial environment addressing tangible real-world needs today, for a better tomorrow. It is focused on health care inclusion in the global south, accelerating access to modern medical care for those who need it most by opening up/growing new markets for distribution of existing solutions and investing in the future of MedTech.
The Jameel Investment Management Company (JIMCO) actively invests in innovative, early-stage and breakthrough ventures and technology, aiming to positively shape the future of core industries driving the global economy through its’ investments that span medical and healthcare industries, from pharmaceuticals and vaccines to cutting-edge medical technology, along with emergent technologies across FinTech, InsurTech, electric vehicles and future mobility solutions.
For further information, visit: https://aljhealth.comand our brand video here. Media Contact: Email email@example.com. For general inquires: firstname.lastname@example.org. For adverse event reporting or medical enquires: email@example.com
Cureleads aspires to transform patients’ lives in MENA by improving access to critical medicines to treat specialty diseases, mainly in cancer, neurology, and rare diseases. Over the next 10 years, the incidence of rare diseases in MENA will become the highest in the world. At the same time, a powerful global confluence of biology and technology is driving dramatic advances in medical therapies to treat these diseases. CURELEADS is dedicated to bringing these advances to patients by partnering with cutting edge pharmaceutical/biotech innovators.
Cureleads is a GloCal Company, a locally based team with decades of experience working for Global Pharma companies, experience that we have used to build personal networks of key stakeholders in business, government and academic medicine, not only in the Middle East and North Africa, but worldwide. We use our experience and relationships to commercialize specialty medicines across the region while adhering to global standards of quality and ethical behavior, combining competence & ethics, biology & technology, innovation & tradition. Critically, we focus on 'doing business with ethics" to ensure proper and sustainable business outcomes. In addition to our own commercialization activities, we partner with the key regional distributors who provide the best logistics capability, account receivables management and regulatory compliance.
For media enquiries, please contact firstname.lastname@example.org. For further information, visit: www.cureleads.com or the Cureleads LinkedIn page.
Copyright Notice and Disclaimer
© Meddist Company Ltd. (Abdul Latif Jameel Health). All rights fully reserved. The Abdul Latif Jameel name, and the Abdul Latif Jameel logotype and pentagon-shaped graphic are trademarks, or registered trademarks of Abdul Latif Jameel IPR Company Limited.
The term “Abdul Latif Jameel” refers broadly to several distinct, separate and independent legal entities. Abdul Latif Jameel is not itself a corporate entity, association or conglomerate run by an overarching parent company but merely refers to a group of distinct and wholly separate legal entities that are collectively referred to as Abdul Latif Jameel. Abdul Latif Jameel is not a corporate group as defined in section 1161(5) of the Companies Act 2006.
This document may contain forward-looking statements. Forward-looking statements are statements regarding matters other than historical fact, such as future results, events, activities, developments or circumstances or the beliefs, plans or expectations of Abdul Latif Jameel Health or Abdul Latif Jameel entities or their respective managements.
Forward-looking statements often can be identified by the use of words such as ‘expect’, ‘project’, ‘anticipate’, ‘plan’, ‘estimate’, ‘believe’, ‘predict’, ‘intend’, ‘potential’, ‘possible’, ‘probable’, ‘likely’, ‘forecast’, ‘guidance’, ‘outlook’, ‘goal’, ‘target’, ‘may’, ‘will’, ‘should’ or ‘could’ or other similar terms or phrases. However, the absence of such words does not mean that a particular statement is not forward looking.
Forward-looking statements are based on expectations and assumptions at the time of such statements and are subject to numerous risks and uncertainties, many of which are outside the control of Abdul Latif Jameel Health or Abdul Latif Jameel entities. Should any of such expectations or assumptions prove incorrect, or should any of such risks or uncertainties materialize, actual future results, events, activities, developments or circumstances may differ materially from those expressed in or implied by forward-looking statements.
Further, any forward-looking statement speaks only as of the date on which it is made, and neither Abdul Latif Jameel Health nor Abdul Latif Jameel assumes, and hereby disclaims, any obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise. All forward-looking statements made by Abdul Latif Jameel Health, Abdul Latif Jameel, or by any person on behalf of any of them, whether communicated in writing, electronically or orally, are qualified in their entirety by the foregoing cautionary statements.
No Offer or Solicitation
This communication is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom.
The Butterfly iQ+ product is not yet registered/marketed in all markets.
 Butterfly iQ+ is a Class IIa / Class B / Class II / Class II / IIa portable ultrasound system designed for diagnostic imaging by trained healthcare professionals. Carefully read and understand all cautions, warnings and operational instructions prior to use.
 UAE Statistical Annual Report 2020 by the UAE Ministry of Health & Prevention